Skip to main content

Table 5 Ongoing Neoadjuvant Clinical Trials Containing ICI with Radiation for Patients with NSCLC

From: Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives

ClinicalTrials.Gov Identifier

Biomarker(s)

Regimen

Phase

Sample Size

Stage

Primary Endpoint

Estimated or Actual Study Period [reference]

NCT03853187

PD-L1 expression

Durvalumab + Zr-89 labelled Durvalumab

II

20

I, II or IIIa

Safety and feasibility

September 19, 2019—April 1, 2022

NCT04933903

PD-L1 expression

Ipilimumab + Nivolumab + SBRT

II

25

IB-IIIB (T2-3N0, T1-T3N1-2)

MPR

July 2021—January 2023

NCT04271384

PD-L1 expression

SABR + Nivolumab

II

30

I

pCR

February 12, 2020—June 29, 2023

NCT02987998

PD-L1 expression

Cisplatin + Etoposide + Pembrolizumab with concurrent radiation

I

9

IIIA

Toxicity

May 18, 2017—January 24, 2024

NCT03871153

PD-L1 expression

Neoadjuvant chemotherapy + radiation + Durvalumab

II

25

III (N2)

PRR

August 2, 2019 – April 2022

NCT03217071

PD-L1 expression

Pembrolizumab + SRT

II

12

I-IIIA

Infiltrating CD3 + T cells/ μm2

October 4, 2017—February 28, 2022

NCT04465968 (DEEP_OCEAN)

PD-L1 expression

CRT + Durvalumab ± Surgery + Durvalumab

III

84

IIB, III

OS

September 1, 2020—August 31, 2030

NCT03965468 (CHESS)

PD-L1 expression

Durvalumab + Carboplatin/Paclitaxel

Followed with either SBRT or surgery

II

47

IV

PFS

November 19, 2019—December 2021

NCT03237377

PD-L1 expression

Durvalumab + radiation

II

32

IIIA

Safety

December 12, 2017 – September 2017

  1. Abbreviations: CRT concurrent chemoradiation therapy, SBRT stereotactic body radiation therapy, pCR pathological complete response, MPR major pathological response, DFS disease-free survival, PFS progression free survival, OS overall survival, PRR pathological response rate